Hosted on MSN1mon
FDA accepts Sobi North America’s thrombocytopenia therapy sNDAThe US Food and Drug Administration (FDA) has accepted Sobi North America’s avatrombopag (DOPTELET) supplemental new drug application (sNDA ... an oral suspension form of the therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback